Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus Chemotherapy as Conversion Therapy in Unresectable EGFR+ Stage III NSCLC
NCT06709859Phase 2Recruiting
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC). Started May 2025; status: recruiting.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06709859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709859.